Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®

Inclusion Criteria

• •Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
• •The decision to initiate treatment with commercially available Esperoct® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
• •Diagnosis of haemophilia A in males or females, no age limitation.
• •New patients who have not previously been exposed to Esperoct®.